Aimmune Therapeutics (AIMT) PT Raised to $45 at JMP Securities
Tweet
Share
E-mailGet Alerts AIMT Hot Sheet
Price: $34.49 --0%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Join SI Premium – FREE
JMP Securities raised its price target on Aimmune Therapeutics (NASDAQ: AIMT) to $45.00 (from $40.00) while maintaining a Market Outperform rating.
Analyst Liisa Bayko said strong efficacy and safety data in the Phase 3 PALISADE trial de-risks shares and bodes well for approval.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades Iflytek Co Ltd (002230:CH) to Hold
- Needham Downgrades ACV Auctions Inc (ACVA) to Hold
- Shoe Station Group (SHOE) PT Lowered to $15 at Williams Trading
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
